# Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines

Study · id `cardio:ct-nct03506815` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03506815](<https://clinicaltrials.gov/study/NCT03506815>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03506815

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

## Technical summary

Registry record NCT03506815. Randomized; no masking; primary purpose prevention. Start 2019-03-15 (actual); primary completion 2020-05-14 (actual). Results posted on 2024-07-05.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 105 participants (enrolled count; ClinicalTrials.gov record NCT03506815, source copy `cardio:ctgov-nct03506815-2024-07-05`, retrieved 2026-10-31)
- Started: 2019-03-15 (actual) (ClinicalTrials.gov record NCT03506815, source copy `cardio:ctgov-nct03506815-2024-07-05`, retrieved 2026-10-31)
- Primary completion: 2020-05-14 (actual) (ClinicalTrials.gov record NCT03506815, source copy `cardio:ctgov-nct03506815-2024-07-05`, retrieved 2026-10-31)
- Completion: 2020-06-14 (actual) (ClinicalTrials.gov record NCT03506815, source copy `cardio:ctgov-nct03506815-2024-07-05`, retrieved 2026-10-31)
- Results first posted: 2024-07-05 (ClinicalTrials.gov record NCT03506815, source copy `cardio:ctgov-nct03506815-2024-07-05`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT03506815, source copy `cardio:ctgov-nct03506815-2024-07-05`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03506815-2024-07-05`, retrieved 2026-10-31)

## The registry's words

- Brief title: Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
- Acronym: TRIM-Line
- Condition: Upper Extremity Deep Vein Thrombosis
- Condition: Central Venous Catheter Thrombosis
- Condition: Cancer
- Intervention (Drug): Rivaroxaban 10 MG
- Lead sponsor: Ottawa Hospital Research Institute
- Lead sponsor class: OTHER
- Collaborator: Queen Elizabeth II Health Sciences Centre
- Collaborator class: OTHER
- Collaborator: University of Alberta
- Collaborator class: OTHER
- Collaborator: Hamilton Health Sciences Corporation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Ottawa Hospital Research Institute (`cardio:org-ottawa-hospital-research-institute`)
- Registry lists this organization as a collaborator: University of Alberta (`cardio:org-university-of-alberta`)
- Registry lists this organization as a collaborator: Hamilton Health Sciences Corporation (`cardio:org-hamilton-health-sciences-corporation`)

## Provenance

Content hash: b9ee0da56bd8d0763698d55b78ff05602e729cb2a4a97fcbfa736c655985e7df
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
